Although MSUT2 has been previously shown to reduce tau pathology in transgenic mice, and here in human tau seeding mouse models, it is not known whether MSUT2 KO would still suppress tau pathology in the presence of the concurrent Aβ plaques found in AD brain, particularly the neuritic plaque (NP) tau pathology found in the vicinity of Aβ deposits. The gene discussed is MAPT; the disease is Alzheimer disease.